Affidea expands in Northern Switzerland with the acquisitions of two renowned radiology and gastroenterology centres

Affidea Group, the pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, announces today its expansion in Switzerland, in the Canton of Aargau, in Baden, with the acquisitions of Röntgeninstitut Baden AG and AmbulanteGastroenterologie Baden AG.

With more than 60 years of experience in radiology, Röntgeninstitut Baden AG is a renowned diagnostic imaging centre located in Baden, close to Zurich, offering the entire range of radiology services, from US and Xray to MRI, CT and Mammography examinations, working with a highly qualified team of 17 administrative and medical professionals.

Ambulante Gastroenterologie Baden AG stands out as a highly distinguished centre specialised in gastroenterology and hepatology. With a dedicated team of 15 experts, the centre has leveraged innovative technologies to enhance its preventive measures against colon cancer.

These two acquisitions allow Affidea to extend its national diagnostic imaging network in German-speaking Switzerland while also creating more comprehensive cancer care pathway, in colorectal and gastroenterology, on top of the existing breast care pathway in Zurich.

Marc-Andre Christinat, CEO of Affidea Switzerland, commented: “I am delighted that we enlarged our presence in the strategic location of Baden, a step that not only strengthens our diagnostic and outpatient service capabilities but also highlights our commitment to enhancing specialised care, particularly in gastroenterology and colorectal cancer. Our approach goes beyond mere expansion; it’s about deepening our commitment to providing Swiss communities with advanced, comprehensive healthcare solutions addressing their medical needs .I look forward to working with the great team of Röntgeninstitut Baden AG and Ambulante Gastroenterologie Baden AG, as we are setting new benchmarks in integrated healthcare services, reinforcing our dedication to deliver exceptional care to every patient, every day, to improve their medical outcomes.”

Dr Charles Niehaus, Deputy CEO of Affidea Group, added: “This is the fifth acquisition we have announced in two months across 5 countries, and I am proud to see how Affidea’s integrated model of care is expanding across our markets. With an expanded footprint in Switzerland, we can address a larger community of patients, offering them access to high-quality medical services and a strong network of community-based centres for their medical needs. These two acquisitions will further enhance our medical portfolio in northern Switzerland while also offering us the possibility of creating more comprehensive cancer pathways benefitting from the know-how of the newly acquired gastroenterology centre. This new expansion is a reflection of our ambition to set new standards in patient care, leveraging our expertise to make a real difference in the lives of the communities we serve.”

Connie Raif, CEO of Doktorhuus Gruppe AG, added: "The divestment of our two renowned outpatient institutes in Baden allows us to streamline our medical service portfolio and refocus entirely on our core expertise in general practitioner medicine. During our ownership, we successfully addressed succession matters and established a highly skilled and entrepreneurial team of doctors. Our commitment to advanced medical technology, patient-friendly environments, and the highest medical standards has been evident throughout. I am convinced that Affidea is the ideal new owner of these two centres, ensuring continuity, and providing added value for the team, patients and the entire region of Baden.

This is the third investment Affidea has announced this year in Switzerland, after the announcement of opening a breast centre in Ticino, which will allow Affidea to expand its expertise in the areas of prevention, diagnosis, treatment and monitoring of breast cancer. Recently, Affidea also announced important investments in state-of-the-art equipment in the Valais region to enhance the capabilities of its medical facilities. The Affidea Sion centre inaugurated its nuclear medicine unit with new state-of-the-art equipment, the Spect-CT scanner and the 1.5 T MRI which will allow patients to have access to tomo-scintigraphy examinations, while the Women's Centre in Sion started offering MRI-guided biopsy and bone densitometry.

With this acquisition in Baden, Affidea reaches 358 centres at the European level, working with more than 14.000 professionals and serving over 13 million patients every year. Only this year, Affidea has announced an impressive growth journey with expansions in Spain, Portugal, Romania, Italy and now Switzerland.

In this transaction, Affidea Group was advised by Niederer Kraft Frey as legal advisors, while KPMG served as financial advisor. The sellers were advised by Sancovia as financial advisors and Walder Wyss as legal advisors.